DATE: April 4, 2006

RE: CLARIFICATION MEMO #1 for PACTG P1056: Study Drug supplier for 3TC oral solution

TO: Pediatric PACTG PIs & Study Coordinators at Sites Participating in PACTG P1056

FROM: PACTG P1056 Protocol Team

The following serves as Clarification Memo #1 for PACTG P1056 " A Phase I/II Comparative Pharmacokinetic Study of the Fixed Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC) and Nevirapine (NVP) as GPO-VIR® Pediatric Chewable Tablets versus the Individual Liquid Formulations in HIV-infected Children ≥ 6 Months to< 13 Years of Age in Thailand” Version 1.0, IND# 71,844, dated February 3, 2006 and Letter of Amendment #1, dated February 21, 2006.

This memo is being issued to notify sites that there is no Clinical Trials Agreement (CTA) associated with P1056 and to provide clarification regarding the supplier for the study agent lamivudine (3TC); Epivir® liquid as stated for Section 5.3 - Drug Supply, Distribution and Pharmacy, under Section 5.31 - Supply on page 40. Please correct to read:

“Lamivudine (3TC); Epivir® liquid (GlaxoSmithKline; 10 mg/mL; (240 mL bottles) will be provided through GPO. Specific gravity of the solution is 1.08 g/mL (typically).”

This information will be added to the next version of the protocol. Please contact the protocol team at actg.teamp1056@fstrf.org if you have any questions.

This Clarification Memo will be available from the PACTG Website (http://pactg.s-3.com). The username is: pactg and the password is: cure (all lower case). Select Protocol Specific Web Page (P1056), and Clarification Memo #1, dated 4/04/06 under Current Protocol Related Documents.

Thank you for your participation in PACTG P1056.

The P1056 Protocol Team